Q1 Earnings Estimate for GLSI Issued By HC Wainwright

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Equities research analysts at HC Wainwright issued their Q1 2027 EPS estimates for Greenwich LifeSciences in a research note issued on Tuesday, July 21st. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.30) for the quarter. HC Wainwright currently has a “Buy” rating and a $69.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.29) EPS and Q4 2027 earnings at ($0.29) EPS.

GLSI has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Wall Street Zen downgraded Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $57.00.

Greenwich LifeSciences Price Performance

NASDAQ:GLSI opened at $13.19 on Wednesday. The firm has a 50-day moving average of $22.43 and a 200-day moving average of $24.45. The company has a market cap of $193.63 million, a PE ratio of -8.40 and a beta of 1.40. Greenwich LifeSciences has a one year low of $7.78 and a one year high of $34.10.

Institutional Trading of Greenwich LifeSciences

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of Greenwich LifeSciences during the fourth quarter valued at about $605,000. Barclays PLC grew its position in Greenwich LifeSciences by 11.8% in the 4th quarter. Barclays PLC now owns 9,744 shares of the company’s stock worth $205,000 after purchasing an additional 1,030 shares in the last quarter. Wells Fargo & Company MN grew its position in Greenwich LifeSciences by 109.6% in the 4th quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after purchasing an additional 4,102 shares in the last quarter. Jane Street Group LLC bought a new stake in Greenwich LifeSciences in the 4th quarter worth about $203,000. Finally, Goldman Sachs Group Inc. increased its stake in Greenwich LifeSciences by 8.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 21,545 shares of the company’s stock valued at $453,000 after buying an additional 1,700 shares during the last quarter. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences News Roundup

Here are the key news stories impacting Greenwich LifeSciences this week:

• Positive Sentiment: UK regulators approved expansion of the company’s Phase III FLAMINGO-01 breast cancer trial into the United Kingdom, potentially adding 5-10 new sites and broadening patient enrollment. Greenwich LifeSciences said the move was supported by patient interest and its collaboration with The Royal Marsden, which could improve visibility and trial momentum for GLSI-100. Article Title
• Positive Sentiment: HC Wainwright maintained a Buy rating and $69 price target on GLSI while slightly lifting its Q2 2026 EPS estimate and reiterating longer-term forecasts. Even though the company is still expected to post losses, the higher estimates and bullish rating suggest analysts remain constructive on the stock’s clinical upside. Article Title
• Neutral Sentiment: HC Wainwright also set out FY2026 and FY2027 EPS estimates, both still negative, indicating Greenwich LifeSciences remains a pre-revenue clinical-stage biotech with ongoing losses. That keeps valuation tied heavily to trial progress rather than near-term earnings. Article Title
• Neutral Sentiment: Investor materials highlighted preliminary FLAMINGO-01 data showing a roughly 70-80% reduction in recurrence rates in one arm of the study, but the company emphasized the results are not final and remain subject to clinical uncertainty. The data are encouraging, but still early enough that investors are likely to wait for more definitive readouts. Article Title

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.